Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
Abstract Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits to reduce both short-term and long-term complic...
Main Authors: | Emily R. Meier, Susan E. Creary, Matthew M. Heeney, Min Dong, Abena O. Appiah-Kubi, Stephen C. Nelson, Omar Niss, Connie Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, Kay L. Saving, John P. Scott, Ravi Talati, Teresa S. Latham, Amanda Pfeiffer, Lisa M. Shook, Alexander A. Vinks, Adam Lane, Patrick T. McGann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-020-04912-z |
Similar Items
-
Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01) -
Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
by: Khayat André Salim, et al.
Published: (2004-01-01) -
The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01) -
The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01) -
The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
by: Luiz Bernardino Lima da Silva, et al.
Published: (2012-01-01)